Skip to content

Evolus EOLS Deferred Tax Assets

Deferred Tax Assets at other companies

AbbVie logo
AbbVieABBV
$137M-94.7%

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Cash & equivalents$49.8M-26.7%
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%
P/S1.6×-0.6×

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's deferred tax assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's deferred tax assets?
Evolus (EOLS) reported deferred tax assets of $23K in Q1 2026.
How has Evolus's deferred tax assets changed year-over-year?
Evolus's deferred tax assets increased by 1050.0% year-over-year, from $2K to $23K.
What is the long-term trend for Evolus's deferred tax assets?
Over 5 years (2020 to 2025), Evolus's deferred tax assets has grown at a -62.8% compound annual growth rate (CAGR), from $3.94M to $28K.
What does deferred tax assets mean?
Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.